Podium to Practice: ASH® 2025 – LYMPHOMA: Final analysis of the Phase III GHSG HD21 trial

Podium to Practice: ASH® 2025 – LYMPHOMA: Final analysis of the Phase III GHSG HD21 trial

Podium to Practice: ASH® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Carolyn Owen

Icon Chair Speaker

Speakers

Dr. Anca Prica

Dr. Kerry Savage

Studies / Trials Discussed

ID 152 – Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma

This program has been made possible through unrestricted support from Eli Lilly and Merck.

Studies/trials discussed:

ID 152 – Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma
Tagged